Global Urinary Incontinence Therapeutics Market Size & Outlook
Global urinary incontinence therapeutics market, 2021-2033 (US$M)
Related Markets
Global urinary incontinence therapeutics market highlights
- The global urinary incontinence therapeutics market generated a revenue of USD 4,322.4 million in 2024 and is expected to reach USD 6,954.1 million by 2033.
- The market is expected to grow at a CAGR (2025 - 2033) of 5.4% by 2033.
- In terms of segment, stress incontinence accounted for a revenue of USD 1,369.5 million in 2024.
- Urge Incontinence is the most lucrative type segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2033.
Global data book summary
| Market revenue in 2024 | USD 4,322.4 million |
| Market revenue in 2033 | USD 6,954.1 million |
| Growth rate | 5.4% (CAGR from 2025 to 2033) |
| Largest segment | Stress incontinence |
| Fastest growing segment | Urge Incontinence |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence, Other |
Other key industry trends
- In terms of revenue, the North America accounted for 40.1% of the global urinary incontinence therapeutics market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
- By country, Mexico is the fastest growing regional market and is projected to reach USD 78.2 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Urinary Incontinence Therapeutics Market Scope
Urinary Incontinence Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | https://www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Ferring | View profile | 5001-10000 | Saint-prex, Vaud, Switzerland, Europe | https://www.ferring.com |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Global urinary incontinence therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to urinary incontinence therapeutics market will help companies and investors design strategic landscapes.
Stress incontinence was the largest segment with a revenue share of 31.68% in 2024. Horizon Databook has segmented the Global urinary incontinence therapeutics market based on stress incontinence, urge incontinence, overflow incontinence, functional incontinence, other covering the revenue growth of each sub-segment from 2021 to 2033.
- Global Urinary Incontinence Therapeutics Type Outlook (Revenue, USD Million, 2021-2033)
- Stress Incontinence
- Urge Incontinence
- Overflow Incontinence
- Functional Incontinence
- Other
- Global Urinary Incontinence Therapeutics Drug Class Outlook (Revenue, USD Million, 2021-2033)
- Anticholinergics
- Beta-3 Adrenoceptor Agonists
- Alpha Blockers
- Estrogen
- Desmopressin
- Tricyclic Antidepressants
- Other drug classes
- Global Urinary Incontinence Therapeutics Gender Outlook (Revenue, USD Million, 2021-2033)
- Male
- Female
- Global Urinary Incontinence Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Global urinary incontinence therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global urinary incontinence therapeutics market databook
-
Our clientele includes a mix of urinary incontinence therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global urinary incontinence therapeutics market , including forecasts for subscribers. This global databook contains high-level insights into Global urinary incontinence therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Global urinary incontinence therapeutics market size, by regions, 2021-2033 (US$M)
Top 10 countries: Urinary incontinence therapeutics market size, 2023 (US$M)
Global urinary incontinence therapeutics market share, by gender, 2023 & 2030 (%, US$M)
Urinary incontinence therapeutics market: Opportunity assessment by country
Global urinary incontinence therapeutics market, by region, 2024 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
